Previous studies reported that the administration of the GLP-1R agonist exendin-4 (25 nmol/kg, twice daily) inhibits learning and memory formation through the suppression of synaptic plasticity in the hippocampus of a high fat diet mouse model (Gault et al., 2010
Brains were fixed, cryoprotected, and sectioned for immunofluorescent labeling using anti-Fos antibodies and fluorescent secondary antibodies
Noom Meds GLP-1 Rx Program: A Personalized, Integrated Solution Nooms approach to individualized treatment was designed in consultation with obesity clinicians from the ground up to solve the adherence puzzle and deliver on the full promise of GLP-1 therapy, when a patient is identified to be at higher risk of discontinuation
Stock solutions of test compounds that are water soluble were made up at 20 times the final assay concentration in buffer (including glucose, GEP44, GEP12, exendin-4, PYY 1-36 and insulin)